+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07589634

Phase 2 Randomized Study of Tocilizumab to Prevent Cytokine Release Syndrome in Adults Receiving Ramantamig for Relapsed or Refractory Multiple Myeloma

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

230

Participants Needed

60

Research Sites

134 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial is investigating whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome CRS in people with relapsed or refractory multiple myeloma. CRS is a sudden inflammatory reaction that can cause flu-like symptoms such as fever and tiredness during treatment. The study is a Phase 2, randomized, double-blind, placebo-controlled trial focused on prevention of CRS. Participants will be randomly assigned to receive either tocilizumab plus ramantamig or placebo plus ramantamig. Ramantamig is given as a subcutaneous injection for a finite duration or until the disease progresses or side effects become intolerable. Tocilizumab or placebo is administered as an intravenous injection before ramantamig treatment starts. Two groups are compared one receiving tocilizumab with ramantamig and the other receiving placebo with ramantamig. During the study, participants will be monitored for CRS symptoms and treatment responses up to 38 months. Researchers will assess the percentage of participants alive and free from significant CRS within 28 days after the first dose of ramantamig. Other measures include response rates, duration of response, progression-free survival, and adverse events. Laboratory tests, clinical exams, and safety monitoring are conducted regularly to evaluate the effects and side effects of the treatments.

CONDITIONS

Brief Title

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here